Follow us...


Search News Archives

News Channels


New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature


Events | Webinars



Conferences | Events

Quotient Clinical announces new investment in Translational Pharmaceutics

publication date: Dec 20, 2013
author/source: kdm communications limited

Quotient Clinical – the pioneer of Translational Pharmaceutics™ – has announced a significant expansion of its capacity and capabilities.

Quotient Clinical LogoThis investment is a direct response to the rapid rate of adoption of the Company’s Translational Pharmaceutics platform and unique approach by a growing international client base. 

Translational Pharmaceutics integrates formulation development, real-time manufacturing and clinical testing to offer shorter timelines, reduced costs and increased success rates in early phase drug development. The 25,000 ft2 expansion allows the extension of both the Pharmaceutical Development Laboratory and the Clinical Pharmacology Unit, which now has 85 beds and is accredited for all types of early clinical development programmes by the MHRA. The Company has also invested in spray-drying formulation and manufacturing capabilities – to address the development challenges of poorly soluble drugs – and established an in silico modelling group to support biopharmaceutical customers in defining formulation strategies and assessing in vitro-in vivo correlations (IVIVCs). 

Mark Egerton, CEO of Quotient Clinical, commented: “Improving R&D productivity requires an evolution of traditional drug development processes. Our customers are attracted to our Translational Pharmaceutics platform to improve the efficiency of their early development programmes, and this latest round of investment enables us to extend our platform while continuing to offer rapid project start times.” 

About Quotient Clinical

Quotient Clinical has over 20 years’ experience delivering high quality data to provide innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide, including 17 of the top 20 pharmaceutical companies. Our expertise in Exploratory Clinical Pharmacology, Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™ and Synthesis-to-Clinic™ delivery platforms, adds significant value to client development programs.

more about Translational Pharmaceutics

more about Quotient Clinical



Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd



Media Partners